BoomRay and Novartis sign $900m deal for radioligand therapy
BoomRay focuses on radioligand therapies for precision oncology, spanning candidate discovery and clinical translation activities.
Drug Development
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Made Scientific acquires cell therapy facility in Pennsylvania, US
EC approves Menarini and NewAmsterdam’s obicetrapib therapies
Telix to acquire ITM in deal worth up to $2.35bn
Sandoz and mAbxience agree on emicizumab biosimilar partnership
Ona Therapeutics to develop ADC with WuXi’s payload-linker platform
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
